Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Leases (2020 - 2025)

Anaptysbio filings provide 6 years of Current Leases readings, the most recent being $2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 8.05% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, up 8.05%, and an annual FY2025 reading of $2.1 million, up 8.05% over the prior year.
  • Current Leases hit $2.1 million in Q4 2025 for Anaptysbio, up from $2.0 million in the prior quarter.
  • The five-year high for Current Leases was $2.1 million in Q4 2025, with the low at $555000.0 in Q2 2021.
  • Median Current Leases over the past 5 years was $1.7 million (2023), compared with a mean of $1.7 million.
  • The sharpest move saw Current Leases skyrocketed 340.06% in 2021, then increased 8.05% in 2025.
  • Year by year, Current Leases stood at $1.5 million in 2021, then increased by 8.77% to $1.6 million in 2022, then rose by 8.55% to $1.8 million in 2023, then grew by 8.33% to $1.9 million in 2024, then rose by 8.05% to $2.1 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.1 million, $2.0 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.